Engineered Leucine Decarboxylases for MSUD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Maple Syrup Urine Disease (MSUD) primarily involve dietary restriction of branched-chain amino acids (BCAAs), which is not sufficient to prevent the accumulation of toxic amino acid levels, leading to severe neurological complications and other health issues.
Innovation Solution
Engineered leucine decarboxylase (LDC) polypeptides with enhanced catalytic activity, reduced sensitivity to proteolysis, increased tolerance to low pH environments, and improved storage stability are developed. These polypeptides are designed to provide therapeutic and industrial benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If dietary restriction of branched-chain amino acids is implemented, then toxic amino acid accumulation is reduced, but treatment effectiveness is insufficient and neurological complications still occur
Solution Approach 1:
The patent introduces leucine decarboxylase as a mediator enzyme that converts toxic leucine into a less harmful compound. This intermediary substance approach allows the body to process and eliminate toxic amino acids metabolically rather than relying solely on dietary restriction, thereby improving treatment reliability while maintaining lower toxic levels.
Solution Approach 2:
The patent replaces the mechanical approach of dietary restriction with a biochemical mechanism - introducing engineered leucine decarboxylase that catalyzes the decarboxylation of leucine. This substitution transforms the treatment from external dietary control to internal metabolic processing, achieving more reliable toxin elimination.
2Productivity
If wild-type LDC is used, then catalytic activity is provided, but the enzyme shows sensitivity to proteolysis and low pH environments
Solution Approach 1:
The patent applies parameter changes by modifying amino acid sequences of leucine decarboxylase to alter its biochemical properties. Through site-directed mutagenesis and sequence optimization, the engineered variants achieve improved resistance to proteolysis and enhanced stability at low pH while preserving catalytic activity, directly resolving the stability-activity trade-off.
Solution Approach 2:
The patent creates composite enzyme structures by combining functional domains and applying molecular engineering techniques. The engineered LDC variants incorporate stabilizing amino acid compositions and structural modifications that create a more robust enzyme composite, resistant to degradation while maintaining catalytic function.
3Productivity
If conventional LDC is used, then basic catalytic function is achieved, but storage stability is poor
Solution Approach 1:
The patent modifies physical and chemical parameters of the LDC enzyme through amino acid sequence engineering. These parameter changes include optimizing hydrophobicity, charge distribution, and structural rigidity to enhance storage stability while preserving the catalytic function, allowing the enzyme to remain stable under various storage conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered LDC polypeptides effectively manage toxic amino acid levels, potentially reducing the severity of MSUD symptoms and improving patient outcomes. Additionally, they offer improved stability and performance in various applications.
Implementation Method 1
Engineered leucine decarboxylase (LDC) polypeptides... optimized to provide enhanced catalytic activity
Data Source
AI summary
The present invention provides engineered leucine decarboxylase (LDC) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered leucine decarboxylase (LDC) polypeptides. In some embodiments, the engineered LDC polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis, and/or increased tolerance to low pH environments. In some embodiments, the engineered LDC polypeptides are optimized to provide improved storage stability. The present invention also provides methods for the use of the compositions comprising the engineered LDC polypeptides for therapeutic and industrial purposes.